Dayvigo (Lemborexant) Regulatory Status: US, EU, Canada, and UK

What Is Lemborexant and How Does It Work?

Lemborexant blocks orexin-A and orexin-B from binding to their OX1R and OX2R receptors in the brain, reducing the wakefulness signals that keep people awake. Unlike benzodiazepines or Z-drugs, it does not broadly suppress the central nervous system. The result is faster sleep onset and better sleep maintenance with a pharmacological target that is specific to the arousal pathway. Orexin system neuropharmacology is detailed in the FDA pharmacology review for Dayvigo.

The Orexin System and Wakefulness

Orexinergic neurons in the lateral hypothalamus fire during wakefulness and are nearly silent during sleep. In insomnia, this system may remain overactive at bedtime, preventing sleep onset. Lemborexant's competitive antagonism at both OX1R and OX2R attenuates that drive. The selectivity for orexin receptors over GABA-A, histamine H1, dopamine, and serotonin receptors is documented in the Eisai preclinical data submitted to the FDA. GABA-A receptor binding profiles for orexin antagonists are discussed in the published pharmacology literature.

Pharmacokinetics Relevant to Next-Morning Function

Lemborexant reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours after an oral dose. Its mean terminal half-life is roughly 17 to 19 hours at the 10 mg dose, which is longer than suvorexant's half-life of approximately 12 hours. This longer half-life informed the dose-selection strategy: the 5 mg dose was designed to balance efficacy with residual sedation risk the following morning. The FDA label recommends starting at 5 mg in most patients, with escalation to 10 mg if the lower dose is not adequately effective. The FDA prescribing information for lemborexant summarizes these PK parameters.

Comparison to Other Dual Orexin Receptor Antagonists

Suvorexant (Belsomra) was the first FDA-approved DORA, cleared in 2014. Lemborexant follows as the second DORA to reach US approval. A key clinical distinction: SUNRISE-1 specifically measured next-day driving performance (a patient-reported and objective outcome), finding that lemborexant 10 mg did not impair driving at 9 hours post-dose compared to zolpidem extended-release 6.25 mg. Zolpidem ER produced statistically significant driving impairment at the same time point (P<0.001 vs. Lemborexant 10 mg). These driving simulation data are available in the SUNRISE-1 publication in JAMA Network Open.

US FDA Approval: What the Label Actually Says

The FDA approved lemborexant on December 20, 2019, under NDA 212028. The approved indication is treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. Two doses are approved: 5 mg and 10 mg, taken orally no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening.

Scheduling and Controlled Substance Classification

The Drug Enforcement Administration placed lemborexant in Schedule IV, the same schedule as benzodiazepines and other DORAs. This classification reflects a recognized but relatively low abuse potential. In clinical studies submitted for scheduling review, lemborexant showed less subjective drug-liking than triazolam (a Schedule IV benzodiazepine) in recreational sedative users. The DEA scheduling order for lemborexant is published in the Federal Register and referenced via the FDA drug page.

Black Box Warning and Key Label Restrictions

The FDA label carries a boxed warning for complex sleep behaviors, including sleepwalking, sleep driving, and other behaviors while not fully awake. Patients who experience any complex sleep behavior should discontinue the drug permanently. The label also contraindicates use in patients with narcolepsy (because orexin signaling is already deficient in narcolepsy type 1). Use is not recommended in patients with severe hepatic impairment. A dose reduction to 5 mg is advised for patients taking moderate CYP3A inhibitors. Full contraindication and warning language is in the FDA prescribing information.

Post-Marketing Requirements

The FDA required Eisai to conduct post-marketing studies on abuse potential and on use in adolescent patients. As of the most recent FDA drug page update, those studies are ongoing. Post-marketing requirements are tracked on the FDA's drug safety page.

Health Canada Approval: Schedule IV in Canada

Health Canada authorized lemborexant for sale in Canada in 2020 under the brand name Dayvigo, with the same adult insomnia indication as the US label. Canadian scheduling places lemborexant in Schedule IV under the Controlled Drugs and Substances Act, consistent with US DEA scheduling.

Canadian Dosing and Prescribing Guidance

The Health Canada product monograph mirrors the FDA label on starting dose (5 mg), maximum dose (10 mg), and the restriction to patients with at least 7 hours remaining before waking. Prescribers in Canada must be aware that the product monograph specifically notes increased exposure in patients of East Asian ancestry due to CYP3A4 pharmacogenomic differences, with a recommended starting dose of 5 mg in this population and caution around escalation to 10 mg. The Health Canada product monograph is accessible through the Drug Product Database.

Provincial Formulary Coverage

Formulary coverage varies across Canadian provinces. As of 2024, lemborexant is not universally listed on provincial public drug plans, meaning some patients pay out-of-pocket or require a Special Authorization request. Ontario's Drug Benefit formulary and British Columbia's PharmaCare each have separate listing criteria. Clinicians should verify current formulary status before prescribing to patients with public drug coverage.

EU (EMA) Status: No Approval as of Mid-2024

The European Medicines Agency has not approved lemborexant. Eisai has not completed a centralized marketing authorization procedure in the EU for this molecule as of July 2024. European clinicians who treat insomnia work within a different approved-drug field: melatonin (Circadin, approved for patients 55 and older), doxylamine, short-term benzodiazepines, and Z-drugs (zopiclone, zolpidem) remain the primary pharmacological options accessible under EU marketing authorizations.

Why the EMA Gap Matters Clinically

The absence of EU approval means that no lemborexant can be routinely prescribed or dispensed through standard EU pharmaceutical supply chains. Named-patient or compassionate-use pathways exist in some EU member states but are administratively complex and not a reliable access route. Clinicians in Germany, France, Spain, or elsewhere in the EU should not anticipate routine lemborexant access without a change in regulatory status. EMA's centralized procedure database can be searched to verify current approval status for any molecule.

Suvorexant as the Closest Available DORA in Some Markets

Suvorexant holds FDA approval in the US and was approved in Japan (where Eisai is headquartered), but it also lacks EMA approval. No DORA has centralized EU marketing authorization as of this writing. European prescribers seeking a non-benzodiazepine, non-Z-drug option for insomnia currently rely on low-dose doxepin (approved in the US but not widely available in the EU) or off-label options. The EMA's published guidance on insomnia medicines reflects this field.

UK MHRA Status: Not Approved Post-Brexit

The UK Medicines and Healthcare products Regulatory Agency operates independently of the EMA since Brexit became effective. Lemborexant holds no MHRA marketing authorization as of July 2024. The UK's approved insomnia pharmacotherapy list includes short-term benzodiazepines, zopiclone, zolpidem, and melatonin (Circadin) for over-55s, consistent with NICE guidance. NICE Clinical Guideline NG215 on insomnia treatment was published in 2021 and covers current UK pharmacotherapy options.

NICE Guidance and CBT-i as First Line

NICE NG215 (2021) explicitly states that cognitive behavioral therapy for insomnia (CBT-i) should be offered before drug treatment in adults. When drug treatment is indicated, NICE recommends the shortest effective duration at the lowest effective dose. Because lemborexant is not MHRA-approved, it does not appear in the NICE medicines comparison tables for insomnia. UK clinicians who wish to use it would need to manage unlicensed prescribing pathways with associated liability and formulary restrictions.

SUNRISE-1: The Key Trial That Supported FDA Approval

SUNRISE-1 (N=291) was a Phase 3, randomized, double-blind, placebo and active-controlled trial published in JAMA Network Open in 2019 that measured both subjective and objective sleep outcomes over 29 nights. The full trial is available at PubMed. Participants were adults aged 22 to 88 with insomnia disorder. They received lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo.

Primary and Secondary Endpoints

The primary endpoint was subjective sleep onset latency (sSOL) at the end of the first treatment month. Both lemborexant doses reduced sSOL significantly versus placebo. Lemborexant 10 mg reduced sSOL by a mean of 17.7 minutes versus placebo (P<0.001). Lemborexant 5 mg reduced sSOL by a mean of 14.9 minutes versus placebo (P<0.001). Wake after sleep onset (WASO) was also improved significantly at both doses.

Secondary endpoints included the driving performance outcome described above: at 9 hours post-dose on night 1 and night 8, zolpidem ER 6.25 mg produced statistically significant driving impairment, while lemborexant 5 mg and 10 mg did not impair driving relative to placebo. This was a meaningful differentiation from the existing standard of care at the time of approval.

SUNRISE-2 and Longer-Term Data

SUNRISE-2 (N=949) extended the evidence base to 12 months of treatment, demonstrating sustained efficacy and an acceptable safety profile over the longer term. SUNRISE-2 data are available on PubMed. The 12-month trial found no evidence of tolerance development (no dose escalation was needed to maintain effect), which supports lemborexant's mechanistic advantage over benzodiazepines that produce tolerance through GABA-A receptor downregulation.

Safety Profile: What Distinguishes Lemborexant from Older Sleep Drugs

Lemborexant's most common adverse event in trials was somnolence, reported in approximately 10 to 17 percent of patients at the 10 mg dose versus 1 to 3 percent on placebo. Headache and dizziness were the next most frequent events. Rates of next-morning somnolence were dose-dependent: the 5 mg dose produced somnolence rates closer to placebo than did the 10 mg dose.

Rebound Insomnia and Dependence Risk

One concern with traditional insomnia drugs is rebound insomnia upon discontinuation. In SUNRISE-2, abrupt discontinuation of lemborexant at month 12 did not produce clinically meaningful rebound insomnia based on sleep diary measures. This finding is consistent with the mechanism: orexin antagonism does not cause receptor upregulation in the way that chronic GABA-A agonism does. Discontinuation data are described in the SUNRISE-2 publication.

Special Populations: Elderly Patients

Adults 65 and older are a key prescribing population for insomnia drugs, and the FDA label does not require a dose adjustment for age alone. However, the label notes that older patients may be more sensitive to CNS effects. SUNRISE-1 enrolled participants up to age 88, providing some evidence in elderly adults. The American Geriatrics Society Beers Criteria lists benzodiazepines and Z-drugs as potentially inappropriate medications in older adults; DORAs including lemborexant are not listed as drugs to avoid in the elderly, which may support their use in this population. The 2023 Beers Criteria update is available through the AGS.

Prescribing Decision Framework: Which Patients Are Candidates for Lemborexant?

Clinicians prescribing for adult insomnia disorder can use the following criteria to identify appropriate lemborexant candidates.

Step 1. Confirm CBT-i has been offered or attempted. Both NICE NG215 and American Academy of Sleep Medicine (AASM) guidelines position CBT-i as the first-line treatment. The AASM clinical practice guideline for pharmacologic treatment of chronic insomnia was published in the Journal of Clinical Sleep Medicine. Pharmacotherapy is appropriate when CBT-i is unavailable, declined, or insufficient.

Step 2. Screen for contraindications. Narcolepsy is an absolute contraindication. Severe hepatic impairment precludes use. Screen for CYP3A inhibitors (strong inhibitors such as ketoconazole contraindicate use; moderate inhibitors require dose reduction to 5 mg).

Step 3. Select the starting dose. The FDA label recommends 5 mg for most patients. East Asian patients and those taking moderate CYP3A inhibitors should start at 5 mg and use caution with escalation. Patients with comorbid respiratory conditions (mild-to-moderate obstructive sleep apnea or COPD) were studied in dedicated trials and can use the standard dose with monitoring.

Step 4. Confirm jurisdiction of prescribing. Lemborexant is available in the US (Schedule IV) and Canada (Schedule IV). It is not accessible through standard prescribing channels in the EU or UK. US and Canadian telehealth prescribers can legally prescribe it where state/provincial licensing permits controlled-substance telehealth prescribing.

Step 5. Reevaluate at 4 weeks. The FDA label does not specify a maximum treatment duration, unlike older benzodiazepine labels. SUNRISE-2 demonstrated 12-month tolerability. Still, clinical reassessment at 4 weeks is standard of care to confirm continued benefit and absence of complex sleep behaviors.

Summary of Global Regulatory Status at a Glance

The table below summarizes current regulatory positions across the four major English-speaking jurisdictions.

| Jurisdiction | Regulatory Body | Status | Approved Doses | Schedule | |---|---|---|---|---| | United States | FDA | Approved (Dec 20, 2019) | 5 mg, 10 mg oral | DEA Schedule IV | | Canada | Health Canada | Approved (2020) | 5 mg, 10 mg oral | CDSA Schedule IV | | European Union | EMA | Not approved | N/A | N/A | | United Kingdom | MHRA | Not approved | N/A | N/A |

FDA approval history for NDA 212028 is available on the FDA's Drugs@FDA database.